Fluzoparib plus apatinib for recurrent ovarian cancer maintenance
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests two oral medications (fluzoparib and apatinib) taken daily as maintenance therapy after your ovarian cancer has responded to chemotherapy. The goal is to keep the cancer from returning for as long as possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a specific type of ovarian, fallopian tube, or primary peritoneal cancer (high-grade serous or certain endometrioid types)
- You have completed 2 or 3 rounds of platinum-based chemotherapy and your cancer shrank or disappeared, but then returned at least 6 months later
- Your daily functioning is good (able to care for yourself and be active), as measured by an ECOG score of 0 or 1
- You have not had a bowel blockage in the last 3 months and do not need drainage for fluid in the belly or chest (unless it was over 2 months ago)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two targeted therapies, fluzoparib (a PARP inhibitor) and apatinib (a blood vessel blocker), as maintenance treatment after initial chemotherapy for advanced ovarian cancer. The goal is to see if this combination helps keep the cancer from coming back longer than usual.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
This trial tests a combination of two oral medications (fluzopril and apatinib) as maintenance therapy after chemotherapy, for patients with platinum-resistant ovarian cancer. The goal is to see if this combo helps keep the cancer from growing longer than usual.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
This trial tests two oral medications given after your first round of chemotherapy. The goal is to see if taking these drugs regularly can keep the cancer from coming back.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
Hear when a new Relapsed Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.